Inflammatory Bowel Diseases: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Inflammatory Bowel Diseases: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

  • 181 Pages | 12-Aug-18 | Format:PDF | Last Updated: 12-Aug-18
  • GervanoRA’s pipeline analysis and opportunity assessment report “Inflammatory Bowel Diseases: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018” analyzed and assessed Inflammatory Bowel Diseases pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Inflammatory Bowel Diseases industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Unmet needs and Opportunities
    • Epidemiology and Epidemiology forecast till 2028
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Patent Analysis of Pipeline Molecules
    • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
    • Clinical Trials Summary
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Drug Descriptions along with Development milestones (Past and Future)
    • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities
    Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals

  • TABLE OF CONTENTS
    1 INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2 EXECUTIVE SUMMARY
    2.1. REPORT MAJOR FINDINGS
    2.2. KEY PIPELINE EVENTS 2019-2028
    3 DISEASE OVERVIEW
    3.1. DEFINITION AND SYMPTOMS
    3.2. DISEASE CAUSE AND CLASSIFICATION
    3.3. DISEASE DIAGNOSIS
    3.4. TREATMENT ALGORITHMS AND GUIDELINES
    3.5. EPIDEMIOLOGY AND DISEASE BURDEN
    3.6. EPIDEMIOLOGY FORECAST
    3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
    3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
    4 MARKET OVERVIEW
    4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    4.2. NEW DRUG APPROVALS (EMA) SINCE 2010
    4.3. NEW DRUG APPROVALS (US FDA) SINCE 2010
    5 PIPELINE ANALYSIS
    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    5.1.1. PRE-REGISTRATION MOLECULES
    5.1.2. PHASE 3 MOLECULES
    5.1.3. PHASE 2 MOLECULES
    5.1.4. PHASE 1 MOLECULES
    5.1.5. PRECLINICAL MOLECULES
    5.1.6. EARLY R&D MOLECULES
    5.1.7. INACTIVE MOLECULES
    5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    5.2.1. UNMET NEEDS AND OPPORTUNITIES
    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY DRUG CLASS
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    5.5.1. UNMET NEEDS AND OPPORTUNITIES
    5.6. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES
    5.6.1. PIPELINE MOLECULES DEVELOPING BY COMPANIES
    6 ESTIMATED APPROVAL TIMELINES
    6.1. METHODOLOGY
    6.2. ESTIMATED APPROVAL TIMELINES US & EX-US
    7 CLINICAL TRIAL SUMMARY
    7.1. KEY PHASE 2 CLINICAL TRIAL RESULTS
    7.2. ONGOING CLINICAL TRIALS SUMMARY
    7.2.1. PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
    7.2.2. PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
    7.2.3. PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
    7.3. PLANNED CLINICAL TRIALS SUMMARY
    7.3.1. PLANNED PHASE 3 CLINICAL TRIALS
    7.3.2. PLANNED PHASE 2 CLINICAL TRIALS
    7.3.3. PLANNED PHASE 1 CLINICAL TRIALS
    7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
    7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS (2013-2018)
    7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS (2013-2018)
    7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS (2013-2018)
    8 WITHDRAWN AND TERMINATED PROJECTS
    8.1. WITHDRAWN CLINICAL TRIALS
    8.2. TERMINATED CLINICAL TRIALS
    9 CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    9.1. ESTABLISHED COMPANIES
    9.2. ESTABLISHED COMPANY PROFILE AND SWOT
    9.3. EMERGING COMPANIES
    9.4. KEY EMERGING COMPANY PROFILES
    9.5. UNIVERSITIES AND INSTITUTES
    10 ABBREVIATIONS

    LIST OF TABLES:

    TABLE 1: LOCATION BASED DISEASE CLASSIFICATION
    TABLE 2: BEHAVIOURAL BASED DISEASE CLASSIFICATION
    TABLE 3: INTERNATIONAL DEFINITIONS FOR CROHN’S DISEASE BY AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG)
    TABLE 4: INTERNATIONAL DEFINITIONS FOR CROHN’S DISEASE BY EUROPEAN CROHN’S AND COLITIS ORGANISATION (ECCO)
    TABLE 5: INTERNATIONAL DEFINITIONS FOR ULCERATIVE COLITIS BY AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG)
    TABLE 6: INTERNATIONAL DEFINITIONS FOR ULCERATIVE COLITIS BY EUROPEAN CROHN’S AND COLITIS ORGANISATION (ECCO)
    TABLE 7: INTERNATIONAL DEFINITIONS FOR ULCERATIVE COLITIS BY JAPANESE SOCIETY OF GASTROENTEROLOGY
    TABLE 8: IBD EPIDEMIOLOGY (2016), FORECAST (2017-2028)
    TABLE 9: MAJOR ACQUISITIONS AND MERGERS IN IBD THERAPEUTIC AREA SINCE 2012
    TABLE 10: MAJOR COLLABORATIVE AGREEMENTS IN IBD THERAPEUTIC AREA
    TABLE 11: MAJOR LICENSING AGREEMENTS IN MS THERAPEUTIC AREA
    TABLE 12: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN IBD THERAPEUTIC AREA
    TABLE 13: EMA APPROVED DRUGS SINCE 2010
    TABLE 14: EMA APPROVED BIOSIMILARS SINCE 2010
    TABLE 15: US FDA APPROVED DRUGS SINCE 2010
    TABLE 16: US FDA APPROVED BIOSIMILARS SINCE 2010
    TABLE 17: COMPANY PIPELINE MOLECULES BY PHASE OF DEVELOPMENT
    TABLE 18: PHASE 3 PIPELINE MOLECULES
    TABLE 19: PHASE 2 PIPELINE MOLECULES
    TABLE 20: PHASE 1 PIPELINE MOLECULES
    TABLE 21: PRECLINICAL STAGE PIPELINE MOLECULES
    TABLE 22: EARLY R&D PIPELINE MOLECULES
    TABLE 23: INACTIVE MOLECULES
    TABLE 24: IBD DRUG PIPELINE BY ORAL AS ROUTE OF ADMINISTRATION
    TABLE 25: IBD DRUG PIPELINE BY INJECTABLE AS ROUTE OF ADMINISTRATION
    TABLE 26: IBD DRUG PIPELINE, IMMUNOMODULATORS
    TABLE 27: IBD DRUG PIPELINE, ANTI-INFLAMMATORY
    TABLE 28: MOLECULES DEVELOPED BY COMPANIES
    TABLE 29: LIST OF UNIVERSITIES AND INSTITUTES WITH PIPELINE MOLECULES
    TABLE 30: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
    TABLE 31: UPADACITINIB (ABT-494) PHASE 2 CLINICAL TRIALS STUDY DESIGN
    TABLE 32: RESULTS FROM 52-WEEK CELEST STUDY, UPADACITINIB (ABT-494)-ABBVIE
    TABLE 33: APREMILAST (OTEZLA) PHASE 2 CLINICAL TRIALS STUDY DESIGN
    TABLE 34: MIRIKIZUMAB (LY3074828) PHASE 2 CLINICAL TRIALS STUDY DESIGN
    TABLE 35: RESULTS FROM 12- WEEK STUDY, MIRIKIZUMAB (LY3074828) – ELI LILLY & COMPANY
    TABLE 36: PHASE 3 ONGOING CLINICAL TRIALS
    TABLE 37: PHASE 2 ONGOING CLINICAL TRIALS
    TABLE 38: PHASE 1 ONGOING CLINICAL TRIALS
    TABLE 39: PLANNED PHASE 3 CLINICAL TRIALS FOR IBD
    TABLE 40: PLANNED PHASE 2 CLINICAL TRIALS FOR IBD
    TABLE 41: PLANNED PHASE 1 CLINICAL TRIALS FOR IBD
    TABLE 42: RECENTLY COMPLETED PHASE 3 TRIALS (2013-2018)
    TABLE 43: RECENTLY COMPLETED PHASE 2 TRIALS (2013-2018)
    TABLE 44: RECENTLY COMPLETED PHASE 1 TRIALS (2013-2018)
    TABLE 45: WITHDRAWN CLINICAL TRIALS FOR IBD
    TABLE 46: TERMINATED CLINICAL TRIALS FOR IBD
    TABLE 47: COMPANY OVERVIEW; PFIZER
    TABLE 48: MAJOR PRODUCTS; PFIZER
    TABLE 49: PFIZER’S PATENT EXPIRY THREAT
    TABLE 50: LIST OF UNIVERSITIES AND INSTITUTES

    LIST OF FIGURES:

    FIGURE 1: KEY PIPELINE EVENTS BY HIGHEST STAGE OF DEVELOPMENT
    FIGURE 2: IBD EPIDEMIOLOGY (2016), FORECAST (2017-2028)
    FIGURE 3: OVERALL DEALS ACTIVITY IN IBD THERAPEUTIC AREA
    FIGURE 4: COMPANIES WITH NUMBER OF DEALS
    FIGURE 5: PIPELINE MOLECULES MIX FOR IBD
    FIGURE 6: IBD DRUG PIPELINE ANALYSIS BY GEOGRAPHY
    FIGURE 7: IBD DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINSTRATION

Pricing

Individual Pricing $2500

Corporate Pricing $2500

Enterprise Pricing $2500

(We are offering all the above license types for a single price!!)